ClinicalTrials.gg
RecruitingNCT05589701COMBATUpdated Mar 5, 2026

Comparing SBRT to CRT in Patients With Spinal Metastases

An observational study in Spinal Metastases, sponsored by University Health Network, Toronto. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-03-05.

Sponsored by University Health Network, Toronto · Observational

How we know

From the registry’s dates

  • Started Dec 2022; still recruiting 3 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Neoplasm Metastasis by University Health Network, Toronto — 10 open to participants now, 15 under way, 2 of them phase 3. Neoplasm Metastasis · University Health Network, Toronto.

Started
2022
with 1 other
Observational
9 of 36
4 open now
Primary completion
2027-12
later than 8 of 14 live
Registered
28th of 36
by date

Among the 36 studies in Neoplasm Metastasis by University Health Network, Toronto, this one is one of 2 that started in 2022, is one of 9 observational ones, reaches primary completion later than 8 of the 14 other live ones, and was the 28th registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

10 of the 36 studies in Neoplasm Metastasis by University Health Network, Toronto are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Neoplasm Metastasis by University Health Network, Toronto, or all of them as a file.
02

Study summary

This is a single institutional registry-based, prospective, observational study to describe radiation oncologists' decision making during evaluation of patients and to compare real-world outcomes of SBRT vs CRT.

A registry-based trial involves observing the effect of something without manipulating it.

Read the detailed description

The purpose of this study is to study the differences between CRT and SBRT. The investigator's are assessing radiation oncologists' decision-making during the evaluation of patients with spinal metastases by requesting radiation oncologists complete a questionnaire. Additionally, the investigator's will compare outcomes, including local progression, pain response and overall survival between SBRT and CRT. By collecting this information, the investigator's will develop an evidence-based algorithm that may be used to support medical decision-making for others with spinal metastases in the future.

03

Conditions studied

  • Spinal Metastases

Browse trials for

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who have MRI- or CT-documented spinal metastases and are suitable for receiving radiation therapy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults 18 years of age or older.
  • Patients seen at the Princess Margaret Cancer Centre with painful spinal amenable to radiation treatment.
  • Confirmation of diagnosis: a) Known/documented prior histological cancer diagnosis
  • Able to provide written consent
  • performance status 0-3

Exclusion criteria

Exclusion Criteria:

  • Prior radiotherapy, with fields overlapping, resulting in excessive doses to organs at risk
  • Lymphoma, myeloma or germ cell
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes

Groups and cohorts

  • Stereotactic Radiotherapy (SBRT)

    Standard of care stereotactic radiotherapy.

    Radiation: Radiotherapy

  • Conventional Radiotherapy (CRT)

    Standard of care conventional radiotherapy.

    Radiation: Radiotherapy

Interventions

  • RadiationRadiotherapy

    Standard of care radiotherapy administered as per institutional guidelines.

06

What researchers measure

Primary outcomes

  1. Describe physician decision-making when making a recommendation for SBRT vs CRT in spine metastasis patients requiring radiation.

    Physician's decision making will be assessed by a questionnaire containing 6 questions, including questions on variations of practice and the role of a number of factors that may influence a physician's recommendation for spine metastasis patients requiring radiation (SBRT vs CRT).

    Time frame: 2 years

Secondary outcomes

  1. Assess local progression free survival.

    Based on available imaging, compare local progression free survival outcomes of patients treated with SBRT vs CRT.

    Time frame: 2 years

  2. Measure pain response

    Using a patient reported scale (0 (no pain) to 10 (worst pain imaginable)), compare pain outcomes of patients treated with SBRT vs CRT.

    Time frame: 2 years

  3. Assess adverse events

    Compare adverse events, collected through standard of care follow up, which occur for patients treated with SBRT vs CRT.

    Time frame: 2 years

  4. Measure overall survival

    Compare overall survival, collected through medical records, for patients treated with SBRT vs CRT.

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Dec 2027, 60 months after the start.

Of 211 non-industry observational studies under Neoplasm Metastasis, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 172. This study's planned 60 months is below that.

Counting every sponsor, half of 242 studies reached it within 66 months; a quarter within 35 and three quarters within 172.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2022
First posted
Oct 21, 2022
StartActual
Dec 12, 2022
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Mar 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05589701
Responsible party
Sponsor
First posted
Oct 21, 2022
Start date
Dec 12, 2022
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Mar 5, 2026

Study contacts

David Shultz, MD
Contact
david.shultz@rmp.uhn.ca
416-946-4501 ext. 2121

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion